Aligos Therapeutics, Inc. (ALGS)
Largest Insider Buys in Sector
ALGS Stock Price History Chart
ALGS Stock Performance
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and …
Insider Activity of Aligos Therapeutics, Inc.
Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $0 and sold $0 worth of Aligos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $13.13M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.
List of Insider Buy and Sell Transactions, Aligos Therapeutics, Inc.
| 2023-10-25 | 7.93M 22.4566% | $0.76 | $6M | +5.73% | ||||
| 2020-10-20 | 10 percent owner | 550,000 1.9863% | $15.00 | $8.25M | +61.44% | |||
| 2020-10-20 | 10 percent owner | 200,000 0.7223% | $15.00 | $3M | +61.44% | |||
| 2020-10-20 | director | 200,000 0.7223% | $15.00 | $3M | +61.44% | |||
| 2020-10-20 | director | 400,000 1.4446% | $15.00 | $6M | +61.44% |
Insider Historical Profitability
| Nuechterlein Carole | 11025941 318.2825% | $39.84 | 1 | 0 | +5.73% | |
| Vivo Capital VIII, LLC | 10 percent owner | 3116658 89.9676% | $39.84 | 1 | 0 | +61.44% |
| Novo Holdings A/S | 10 percent owner | 2614563 75.4738% | $39.84 | 1 | 0 | +61.44% |
| Woiwode Thomas | director | 862444 24.8959% | $39.84 | 1 | 0 | +61.44% |
| Versant Venture Capital VI, L.P. | director | 862444 24.8959% | $39.84 | 1 | 0 | +61.44% |
Institutional Investor Ownership
| Armistice Capital Llc | $6.76M | 8.82 | 6.89M | +0.87% | +$58,344.30 | 0.02 | |
| Ecor1 Capital Llc | $6.26M | 8.18 | 6.39M | 0% | +$0 | 0.04 | |
| Deep Track Capital Lp | $5.98M | 7.81 | 6.1M | 0% | +$0 | 0.03 | |
| Vivo Capital | $3.48M | 4.54 | 3.55M | 0% | +$0 | 0.3 | |
| Adage Capital Partners Gp L L C | $2.42M | 3.16 | 2.46M | New | +$2.42M | <0.01 |